Nafoxidine HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206550

CAS#: 1847-63-8 (HCl)

Description: Nafoxidine, also known as PNU-0011100 and CP-5600, is a partial estrogen antagonist. Nafoxidine competes with endogenous estrogen for binding to specific estrogen receptors. This agent also inhibits angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF); paradoxically, it may enhance angiogenesis in uterine tissue. Nafoxidine also induces oxidative stress, protein kinase C and calcium signaling.


Price and Availability

Size
Price

5mg
USD 260
Size
Price

25mg
USD 690
Size
Price

Nafoxidine HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 206550
Name: Nafoxidine HCl
CAS#: 1847-63-8 (HCl)
Chemical Formula: C29H32ClNO2
Exact Mass: 461.2122
Molecular Weight: 462.03
Elemental Analysis: C, 75.39; H, 6.98; Cl, 7.67; N, 3.03; O, 6.93


Related CAS #: 1847-63-8 (HCl salt)   1845-11-0 (free base)    

Synonym: CP-5600; CP5600; CP 5600; PNU-0011100; PNU 0011100; PNU0011100; U-11,000A; Nafoxidine HCl

IUPAC/Chemical Name: 1-[2-[4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]-pyrrolidine hydrochloride,

InChi Key: HJOOGTROABIIIU-UHFFFAOYSA-N

InChi Code: InChI=1S/C29H31NO2.ClH/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30;/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3;1H

SMILES Code: COC1=CC2=C(C(C3=CC=C(OCCN4CCCC4)C=C3)=C(C5=CC=CC=C5)CC2)C=C1.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Yaz G, Kabadere S, Oztopçu P, Durmaz R, Uyar R. Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro. Am J Clin Oncol. 2004 Aug;27(4):384-8. PubMed PMID: 15289732.

2: De Lorenzo MS, Farina HG, Alonso DF, Gomez DE. Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Res. 2004 May-Jun;24(3a):1737-43. PubMed PMID: 15274349.

3: Maertens C, Droogmans G, Chakraborty P, Nilius B. Inhibition of volume-regulated anion channels in cultured endothelial cells by the anti-oestrogens clomiphene and nafoxidine. Br J Pharmacol. 2001 Jan;132(1):135-42. PubMed PMID: 11156570; PubMed Central PMCID: PMC1572544.

4: De Lorenzo MS, Alonso DF, Gomez DE. Nafoxidine modulates the expression of matrix-metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in endothelial cells. Anticancer Res. 2000 Jan-Feb;20(1A):395-400. PubMed PMID: 10769686.

5: Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996 Jun;10(8):905-12. PubMed PMID: 8666168.

6: Fanidi A, Courion-Guichardaz C, Fayard JM, Pageaux JF, Laugier C. Effects of tamoxifen, tamoxifen metabolites, and nafoxidine on adenosine 3',5'-monophosphate phosphodiesterase: correlations with growth inhibitory activities but not estrogen receptor affinities. Endocrinology. 1989 Sep;125(3):1187-93. PubMed PMID: 2547579.

7: Quarmby VE, Fox-Davies C, Newbold RR, Korach KS. Response of the mouse uterus to nafoxidine stimulation: agonism and antagonism. Biol Reprod. 1988 May;38(4):945-54. PubMed PMID: 3401548.

8: Campbell PS, Satterfield PM. Effect of neonatal exposure to the antioestrogens nafoxidine and CI-628 upon the development of the uterus in the prepubertal rat. J Reprod Fertil. 1988 May;83(1):225-31. PubMed PMID: 3397940.

9: Khar A. Nafoxidine possesses antitumor activity against an ascitic hepatoma. Eur J Cancer Clin Oncol. 1986 Dec;22(12):1475-8. PubMed PMID: 3595673.

10: Galand P, Tchernitchin N, Tchernitchin AN. Dissociation of uterine eosinophilia and water imbibition from other estrogen-induced responses by nafoxidine pretreatment. Mol Cell Endocrinol. 1985 Oct;42(3):227-33. PubMed PMID: 2412910.

11: Trachtenberg J. Androgen receptor content of nafoxidine treated experimentally induced canine prostatic hyperplasia. Clin Invest Med. 1985;8(1):29-34. PubMed PMID: 2580656.

12: Galand P, Tchernitchin N, Tchernitchin AN. Time-course of the effects of nafoxidine and oestradiol on separate groups of responses in the uterus of the immature rat. J Steroid Biochem. 1984 Jul;21(1):43-7. PubMed PMID: 6748655.

13: Galand P, Mairesse N, Roorijck J, Flandroy L. Differential blockade of estrogen-induced uterine responses by the antiestrogen nafoxidine. J Steroid Biochem. 1983 Sep;19(3):1259-63. PubMed PMID: 6194375.

14: Strum JM. Nafoxidine administered to newborn female GR mice arrests the development of their mammary glands. Virchows Arch B Cell Pathol Incl Mol Pathol. 1983;42(2):227-33. PubMed PMID: 6133394.

15: Sala Blanco J, Casas Tineo B, Hidalgo A. [Effects of subacute treatment with clomiphene, ethamoxytriphetol (Mer-25), and nafoxidine on blood calcium and bone density in rats]. Rev Esp Oncol. 1982;29(3):497-503. Spanish. PubMed PMID: 6927021.

16: Alhadi T, Vonderhaar BK. Induction of cryptic lactogenic hormone binding in livers of adult female mice treated neonatally with estradiol or nafoxidine. Endocrinology. 1982 Jan;110(1):254-9. PubMed PMID: 6274621.

17: Attardi B, Palumbo LA. Effects of nafoxidine on the luteinizing hormone surge: temporal distribution of estrogen receptors and induction of cytoplasmic progestin receptors in the hypothalamus-preoptic area, pituitary, and uterus of the immature rat. Endocrinology. 1981 Nov;109(5):1365-74. PubMed PMID: 7297482.

18: Mairesse N, Reiss N, Galand P, Kaye AM. Nafoxidine-responsive uterine protein: further characterization and distinction from the "estrogen-induced" protein (IP). Mol Cell Endocrinol. 1981 Oct;24(1):53-63. PubMed PMID: 6173271.

19: Hamburger AD. Effects of nafoxidine and oestriol on the oestradiol-induced activation of rat liver tryptophan oxygenase and tyrosine aminotransferase and increase in uterine weight. Biochem Pharmacol. 1981 Sep 1;30(17):2485-8. PubMed PMID: 21043251.

20: Stolbach LL, Begg CB, Hall T, Horton J. Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):689-92. PubMed PMID: 6454485.